Key Takeaways
- Tempus AI has obtained FDA 510(k) authorization for ECG-PH, an artificial intelligence system that identifies pulmonary hypertension indicators from conventional 12-lead electrocardiograms.
- ECG-PH represents Tempus’ third cardiovascular AI solution to receive FDA clearance, complementing existing products for detecting atrial fibrillation and reduced ejection fraction.
- Approximately 1% of the general population and up to 10% of seniors over age 65 suffer from pulmonary hypertension.
- The technology serves as a clinical decision support tool and cannot replace comprehensive diagnostic evaluation.
- The system is approved exclusively for patients 40 years or older presenting with cardiovascular symptoms without previous PH diagnosis.
Tempus AI (TEM) has secured FDA 510(k) authorization for its Tempus ECG-PH platform, an artificial intelligence-driven software solution that identifies pulmonary hypertension indicators through analysis of conventional 12-lead electrocardiogram readings.
This authorization represents the company’s third FDA-cleared cardiovascular AI solution. Tempus previously secured regulatory approval for diagnostic tools focused on detecting atrial fibrillation and identifying low ejection fraction.
Pulmonary hypertension develops when blood vessels within the lungs become narrowed and rigid, creating excessive strain on the heart’s right ventricle. The condition impacts approximately 1% of all individuals and affects as many as 10% of the elderly population above 65 years.
The condition often goes undetected due to its subtle presentation. Initial symptoms such as exhaustion and breathing difficulties are commonly dismissed, while definitive diagnosis traditionally requires right heart catheterization, an invasive cardiac procedure.
Tempus ECG-PH addresses this diagnostic gap. The platform examines stationary 12-lead ECG data and identifies markers of increased mean pulmonary artery pressure, a key physiological indicator of PH.
Intended Patient Population
The system is authorized for patients 40 years of age or older presenting with cardiovascular manifestations including dyspnea, exhaustion, thoracic discomfort, or swelling, who have not received a prior PH diagnosis.
The software delivers a binary classification, either detecting the presence of concerning indicators or determining their absence. Healthcare providers must integrate this output with comprehensive patient assessment data.
Tempus emphasizes that this technology functions as an adjunctive tool rather than a definitive diagnostic instrument. Clinicians must consider the AI-generated result together with the original electrocardiogram, patient symptoms, historical test results, and additional clinical information.
The platform is not designed for continuous patient monitoring and cannot process electrocardiograms showing paced cardiac rhythms.
Expanding Cardiovascular AI Capabilities
Brandon Fornwalt, MD, PhD, who serves as Senior Vice President of Cardiology at Tempus, explained that this clearance aligns with the company’s strategic initiative to deploy artificial intelligence for earlier cardiovascular risk detection.
“Pulmonary hypertension has historically been underdiagnosed because early symptoms are non-specific and gold-standard diagnostics are invasive,” Fornwalt said.
Fornwalt emphasized the organization’s objective to assist healthcare providers in recognizing at-risk patients “across the spectrum of cardiovascular disease.”
Tempus maintains one of the world’s most extensive multimodal healthcare data repositories and deploys artificial intelligence solutions across numerous clinical specialties beyond cardiology.
The ECG-PH authorization strengthens a cardiovascular AI suite that now addresses three separate conditions, all utilizing the standard 12-lead electrocardiogram as the data source.
The FDA 510(k) regulatory pathway applies to medical devices demonstrating substantial equivalence to legally marketed predecessor devices, representing a standard approval route for software-based diagnostic technologies.
Tempus ECG-PH has received clearance for deployment in healthcare settings using clinical diagnostic electrocardiogram recordings.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
